Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: A pre-specified analysis from the prodigy study (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study)

JACC: Cardiovascular Interventions

Volumn 7, Issue 1, 2014, Pages 20-28

  Valgimigli, Marco ^a   Tebaldi, Matteo ^b   Borghesi, Marco ^b   Vranckx, Pascal ^c   Campo, Gianluca ^b   Tumscitz, Carlo ^b   Cangiano, Elisa ^b   Minarelli, Monica ^b   Scalone, Antonella ^b   Cavazza, Caterina ^b   Marchesini, Jlenia ^b   Parrinello, Giovanni ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FERRARA   (Italy)

^c VIRGA JESSE HOSPITAL   (Belgium)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

all comer randomized clinical trial; bare metal stent(s); everolimus eluting stent(s); paclitaxel eluting stent(s); zotarolimus eluting stent(s)

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; EVEROLIMUS; PACLITAXEL; ZOTAROLIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; BARE METAL STENT; BLOOD SAMPLING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERPLASIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS; TIME TO TREATMENT; TREATMENT DURATION; ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING CORONARY STENT; HEART DEATH; LOADING DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ALL-COMER RANDOMIZED CLINICAL TRIAL; BARE-METAL STENT(S); BMS; CI; CK-MB; CONFIDENCE INTERVAL; CREATINE KINASE MYOCARDIAL BAND; DES; DRUG-ELUTING STENT(S); EES; EVEROLIMUS-ELUTING STENT(S); MACE; MAJOR ADVERSE CARDIAC EVENT(S); MI; MYOCARDIAL INFARCTION; PACLITAXEL-ELUTING STENT(S); PES; ST; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; TLR; TVR; ZES-S; ZOTAROLIMUS-ELUTING ENDEAVOR SPRINT STENT(S); ZOTAROLIMUS-ELUTING STENT(S);

AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPERPLASIA; ITALY; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOINTIMA; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892996734     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.09.008     Document Type: Article

References (28)

1. G.W. Stone, S.G. Ellis, and D.A. Cox et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
2. M. Valgimigli, G. Campo, and G. Percoco et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 2008 1788 1799 (Pubitemid 351549970)
3. A. Kastrati, J. Mehilli, and J. Pache et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 1030 1039 (Pubitemid 46376803)
4. J.V. Tu, J. Bowen, and M. Chiu et al. Effectiveness and safety of drug-eluting stents in Ontario N Engl J Med 357 2007 1393 1402 (Pubitemid 47541971)
5. E.L. Eisenstein, K.J. Anstrom, and D.F. Kong et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168 (Pubitemid 46089732)
6. M. Valgimigli, G. Campo, and S. Gambetti et al. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY) Int J Cardiol 165 2013 134 141
7. E. Kedhi, K.S. Joesoef, and E. McFadden et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
8. G.W. Stone, M. Midei, and W. Newman et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
9. G.W. Stone, A. Rizvi, and W. Newman et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
10. P.W. Serruys, S. Silber, and S. Garg et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
11. M. Valgimigli, G. Campo, and G. Percoco et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY) Am Heart J 160 2010 804 811
12. M. Valgimigli, G. Campo, and M. Monti et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
13. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
14. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455 discussion 1455 (Pubitemid 46648381)
15. E. Camenzind, W. Wijns, and L. Mauri et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405
16. D.E. Kandzari, M.B. Leon, and J.J. Popma et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447 (Pubitemid 44881222)
17. M.B. Leon, D.E. Kandzari, and E.L. Eisenstein et al. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 2 2009 1208 1218
18. M.B. Leon, E. Nikolsky, and D.E. Cutlip et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial J Am Col Cardiol Intv 3 2010 1043 1050
19. D.W. Park, Y.H. Kim, and S.C. Yun et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
20. P.C. Smits, E. Kedhi, and K.J. Royaards et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18
21. T. Kimura, H. Yokoi, and Y. Nakagawa et al. Three-year follow-up after implantation of metallic coronary-artery stents N Engl J Med 334 1996 561 566 (Pubitemid 26066129)
22. T. Kimura, T. Morimoto, and K. Kozuma et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) Circulation 122 2010 52 61
23. Y. Oikawa, J. Yajima, and M.A. Costa et al. Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential "thromborestenosis" phenomenon EuroIntervention 6 2010 380 387
24. K. Kolandaivelu, R. Swaminathan, and W.J. Gibson et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
25. M. Sabate, A. Cequier, and A. Iniguez et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial Lancet 380 2012 1482 1490
26. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
27. M. Valgimigli, M. Borghesi, M. Tebaldi, P. Vranckx, G. Parrinello, and R. Ferrari Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 2013 909 919
28. S.G. Ellis, M.G. Vandormael, and M.J. Cowley et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group Circulation 82 1990 1193 1202